Table 2.
Treatment | Patients | PFS, months | Hazard ratio† | P‐value | ||||
---|---|---|---|---|---|---|---|---|
Group | n | Median | 90% CI | HR | 90% CI | |||
Evaluated by independent radiologist | ||||||||
Prior taxane therapy | No | Nab‐paclitaxel | 71 | 10.9 | 8.5, 12.5 | 1.05 | 0.72, 1.53 | 0.824 |
Docetaxel | 71 | 9.9 | 7.8, 12.6 | |||||
Yes | Nab‐paclitaxel | 27 | 8.4 | 6.9, 12.6 | 1.73 | 0.94, 3.17 | 0.133 | |
Docetaxel | 28 | 15.3 | 11.2, 18.1 | |||||
Evaluated by investigator | ||||||||
Prior taxane therapy | No | Nab‐paclitaxel | 71 | 11.3 | 9.4, 14.2 | 0.73 | 0.51, 1.06 | 0.166 |
Docetaxel | 71 | 9.8 | 7.8, 11.1 | |||||
Yes | Nab‐paclitaxel | 27 | 9.8 | 8.4, 16.5 | 0.99 | 0.56, 1.75 | 0.983 | |
Docetaxel | 28 | 12.5 | 9.3, 15.4 |
Analysis set: full analysis set. †Cox's proportional hazards model was used. CI, confidence interval; HR, hazard ratio; n, number of patients; PFS, progression‐free survival.